Nuria Fernández-Hidalgo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nuria Fernández-Hidalgo has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Benito Almirante
Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
42 shared publications - Nieves Larrosa
Respiratory Viruses Unit, Virology Section, Microbiology Department, Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Vall d’Hebron Institut de Recerca, Barcelona, Spain
13 shared publications - Albert Roque
Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Nuclear Cardiology and Hybrid Cardiovascular Imaging Unit, Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain
12 shared publications - Dolors Rodríguez-Pardo
Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
12 shared publications - Emanuele Durante-Mangoni
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
12 shared publications Francisco Nacinovich
Infectious Diseases, Instituto Cardiovascular Buenos Aires , Buenos Aires , Argentina
11 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- p. 1-11
Sex-related differences in clinical characteristics, management, and outcomes of Enterococcus faecalis bloodstream infection
Objectives: To evaluate whether clinical characteristics and outcomes of patients with Enterococcus faecalis bloodstream infection (EF-BSI) differ by biological sex. Methods: Quasi-experimental study conducted at two hospitals, comprising a retrospective phase (2017–2019) and a prospective intervention phase (2022–2024), including adults with a first episode of monomicrobial EF-BSI. Patients who died within 72 h or were receiving palliative care were excluded. A structured management bundle was implemented in the intervention phase. Clinical features, bundle adherence, and 90-day mortality were compared by sex. Cox regression was used to assess the association between sex and 90-day mortality. Results: Among 250 patients, 77 (31%) were females and 173 (69%) males. Females were younger than males (median 63 [50–76] vs. 73 [63–80] years; p < 0.001). Cardiovascular disease was more frequent in males (30 [39%] vs. 94 [54%]; p = 0.025), whereas immunosuppressive therapy (29 [38%] vs. 35 [20%]; p = 0.004) and connective tissue disease (9 [12%] vs. 2 [1%]; p < 0.001) were more frequent in females. Persistent bacteraemia (2/57 [4%] vs. 30/139 [22%]; p = 0.002) and infective endocarditis (14 [18%] vs. 59 [34%]; p = 0.011) were more frequent in males. Females received fewer bundle measures (5 [3–6] vs. 5 [4–6]; p = 0.028), largely because echocardiography and colonoscopy were less frequently indicated. Ninety-day mortality was 22% (17) in females and 14% (25) in males ( p = 0.136). Female sex was associated with higher 90-day mortality after adjustment (aHR 2.00, 95%CI 1.04–3.83). Conclusions: Further studies should explore the underlying causes of these differences and potential implications for individualized management.
- 14 October 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- p. 1-11
Open AccessSex-related differences in clinical characteristics, management, and outcomes of Enterococcus faecalis bloodstream infection
Objectives: To evaluate whether clinical characteristics and outcomes of patients with Enterococcus faecalis bloodstream infection (EF-BSI) differ by biological sex. Methods: Quasi-experimental study conducted at two hospitals, comprising a retrospective phase (2017–2019) and a prospective intervention phase (2022–2024), including adults with a first episode of monomicrobial EF-BSI. Patients who died within 72 h or were receiving palliative care were excluded. A structured management bundle was implemented in the intervention phase. Clinical features, bundle adherence, and 90-day mortality were compared by sex. Cox regression was used to assess the association between sex and 90-day mortality. Results: Among 250 patients, 77 (31%) were females and 173 (69%) males. Females were younger than males (median 63 [50–76] vs. 73 [63–80] years; p < 0.001). Cardiovascular disease was more frequent in males (30 [39%] vs. 94 [54%]; p = 0.025), whereas immunosuppressive therapy (29 [38%] vs. 35 [20%]; p = 0.004) and connective tissue disease (9 [12%] vs. 2 [1%]; p < 0.001) were more frequent in females. Persistent bacteraemia (2/57 [4%] vs. 30/139 [22%]; p = 0.002) and infective endocarditis (14 [18%] vs. 59 [34%]; p = 0.011) were more frequent in males. Females received fewer bundle measures (5 [3–6] vs. 5 [4–6]; p = 0.028), largely because echocardiography and colonoscopy were less frequently indicated. Ninety-day mortality was 22% (17) in females and 14% (25) in males ( p = 0.136). Female sex was associated with higher 90-day mortality after adjustment (aHR 2.00, 95%CI 1.04–3.83). Conclusions: Further studies should explore the underlying causes of these differences and potential implications for individualized management.
- Open Access
- 17 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 891
Infective Endocarditis in Perceval Sutureless Valves: Incidence, Diagnostic Challenges, and Management: An Expert Opinion Review
Sutureless aortic bioprostheses have become an established alternative for surgical aortic valve replacement, particularly in elderly and high-risk patients. The Perceval (Livanova) valve, the most widely studied sutureless device, offers favorable hemodynamic performance and reduced operative times but introduces specific challenges when prosthetic valve endocarditis (PVE) occurs. Although the incidence of Perceval PVE is low and comparable to that of conventional bioprostheses, this complication is associated with substantial morbidity and mortality. Diagnosis is often complex due to acoustic shadowing on echocardiography, making multimodality imaging with transesophageal echocardiography, cardiac computed tomography, and [18F]-FDG PET/CT essential. Microbiological profiles resemble those of other biological prostheses, but perivalvular extension and early mechanical instability are frequent. Management follows general PVE principles but often requires early surgical intervention because of the valve’s reliance on radial fixation. This review summarizes current evidence on epidemiology, microbiology, diagnostic strategies, treatment, and prognosis of endocarditis involving the Perceval valve, and identifies areas for future research.
- 17 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 891
Open AccessInfective Endocarditis in Perceval Sutureless Valves: Incidence, Diagnostic Challenges, and Management: An Expert Opinion Review
Sutureless aortic bioprostheses have become an established alternative for surgical aortic valve replacement, particularly in elderly and high-risk patients. The Perceval (Livanova) valve, the most widely studied sutureless device, offers favorable hemodynamic performance and reduced operative times but introduces specific challenges when prosthetic valve endocarditis (PVE) occurs. Although the incidence of Perceval PVE is low and comparable to that of conventional bioprostheses, this complication is associated with substantial morbidity and mortality. Diagnosis is often complex due to acoustic shadowing on echocardiography, making multimodality imaging with transesophageal echocardiography, cardiac computed tomography, and [18F]-FDG PET/CT essential. Microbiological profiles resemble those of other biological prostheses, but perivalvular extension and early mechanical instability are frequent. Management follows general PVE principles but often requires early surgical intervention because of the valve’s reliance on radial fixation. This review summarizes current evidence on epidemiology, microbiology, diagnostic strategies, treatment, and prognosis of endocarditis involving the Perceval valve, and identifies areas for future research.
- Open Access
- 26 December 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (2) , 107706
Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study
- 26 December 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (2) , 107706
Open AccessRisk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study
- 31 October 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (3) , 471-488
Infective Endocarditis After Transcatheter Aortic Valve Implantation: Current Challenges in Diagnosis, Management, and Prevention
- 31 October 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (3) , 471-488
Infective Endocarditis After Transcatheter Aortic Valve Implantation: Current Challenges in Diagnosis, Management, and Prevention
- Open Access
- 17 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Endogenous endophthalmitis complicating infective endocarditis: a multicentre case-matched control cohort
Aims: Endogenous endophthalmitis (EE) is a rarely reported complication of infective endocarditis (IE). In an international series, we sought to determine the clinical and microbiological profile, treatment, and outcome of patients presenting with IE-related EE. Methods and results: Cases recorded from 2014 to 2023 in nine centres in Europe and the United States were collected. Results were compared to a matched control group. Conclusion: Sixty-six patients with EE were reported, mean age of 65.2 ± 14.9 years, 71% (n = 47) male. Blood cultures were positive in 97% (64 cases) of patients, with a predominance of streptococci (46%, n = 30). As compared with the control group (n = 264), the EE group presented with more frequent diabetes (35% vs. 21%, P = 0.02), history of cirrhosis (9% vs. 3%, P = 0.04), glomerulonephritis (15% vs. 0.4%, P < 0.001), embolism before admission (92% vs. 55%, P < 0.001), and Janeway lesions (9% vs. 1%, P = 0.002). Streptococcal infection (46% vs. 26%, P = 0.001) was more frequent and Enterococcal infection (0% vs. 18%, P < 0.001) less frequent in the EE group. The main ocular symptoms were a decrease in visual acuity (96%), red eye (55%), and ocular pain (55%). Treatment of EE consisted of intravitreal antibiotic injection in 55 (83%) patients and vitrectomy in 17 (26%). Improvement of visual acuity was observed in 36 (55%) patients. Conclusion: EE is a serious complication of IE with severe residual vision impairment. Patients with IE should be evaluated for ocular complications, since early detection of EE is crucial to prevent delays in management and to preserve visual function.
- 17 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (6)
Open AccessEndogenous endophthalmitis complicating infective endocarditis: a multicentre case-matched control cohort
Aims: Endogenous endophthalmitis (EE) is a rarely reported complication of infective endocarditis (IE). In an international series, we sought to determine the clinical and microbiological profile, treatment, and outcome of patients presenting with IE-related EE. Methods and results: Cases recorded from 2014 to 2023 in nine centres in Europe and the United States were collected. Results were compared to a matched control group. Conclusion: Sixty-six patients with EE were reported, mean age of 65.2 ± 14.9 years, 71% (n = 47) male. Blood cultures were positive in 97% (64 cases) of patients, with a predominance of streptococci (46%, n = 30). As compared with the control group (n = 264), the EE group presented with more frequent diabetes (35% vs. 21%, P = 0.02), history of cirrhosis (9% vs. 3%, P = 0.04), glomerulonephritis (15% vs. 0.4%, P < 0.001), embolism before admission (92% vs. 55%, P < 0.001), and Janeway lesions (9% vs. 1%, P = 0.002). Streptococcal infection (46% vs. 26%, P = 0.001) was more frequent and Enterococcal infection (0% vs. 18%, P < 0.001) less frequent in the EE group. The main ocular symptoms were a decrease in visual acuity (96%), red eye (55%), and ocular pain (55%). Treatment of EE consisted of intravitreal antibiotic injection in 55 (83%) patients and vitrectomy in 17 (26%). Improvement of visual acuity was observed in 36 (55%) patients. Conclusion: EE is a serious complication of IE with severe residual vision impairment. Patients with IE should be evaluated for ocular complications, since early detection of EE is crucial to prevent delays in management and to preserve visual function.
- Open Access
- 27 September 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102505
How to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: The role of [18F]-FDGCT/CT imaging—An international multidisciplinary survey
- 27 September 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102505
Open AccessHow to manage patients receiving long-term suppressive antibiotic treatment for infective endocarditis: The role of [18F]-FDGCT/CT imaging—An international multidisciplinary survey
- Top Cited PapersOpen Access
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (24) , 2275-2288
Infective endocarditis: it takes a team
Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation of injection drug use in many areas of the world. In parallel, advancements in diagnostic and therapeutic options have led to complex strategies in patients’ management. Despite these epidemiologic shifts, clinical trials have been rare and most of the evidence guiding IE management derives from expert consensus or analysis of large registries. Because of this, a multi-disciplinary IE team-based approach has been recommended as the standard of care. The aim of this review is to explore the rationale for a multi-disciplinary team-based approach to the management of IE. This approach has proved to be potentially beneficial based on multiple investigations that have evaluated patient outcomes. In addition, implementation strategies, feasibility and options of the team approach have also been highlighted.
- 11 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (24) , 2275-2288
Top Cited PapersOpen AccessInfective endocarditis: it takes a team
Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation of injection drug use in many areas of the world. In parallel, advancements in diagnostic and therapeutic options have led to complex strategies in patients’ management. Despite these epidemiologic shifts, clinical trials have been rare and most of the evidence guiding IE management derives from expert consensus or analysis of large registries. Because of this, a multi-disciplinary IE team-based approach has been recommended as the standard of care. The aim of this review is to explore the rationale for a multi-disciplinary team-based approach to the management of IE. This approach has proved to be potentially beneficial based on multiple investigations that have evaluated patient outcomes. In addition, implementation strategies, feasibility and options of the team approach have also been highlighted.
- Open Access
- 25 January 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (4) , 107450
Safety of ceftobiprole in patients with impaired renal, hepatic or immune function: A multinational retrospective hospital chart review (RETRACE study)
- 25 January 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 65 (4) , 107450
Open AccessSafety of ceftobiprole in patients with impaired renal, hepatic or immune function: A multinational retrospective hospital chart review (RETRACE study)
- Open Access
- 24 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 14 (1) , 4
Correction: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874
- 24 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 14 (1) , 4
Open AccessCorrection: Kirkegaard-Biosca et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics 2024, 13, 874